Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis

Solmaz Razi; Katayoon Ghasemi; Mohsen Masoodi

doi:doi:10.11648/j.ijbecs.20210703.12

| Peer-Reviewed

Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis

Solmaz Razi, Katayoon Ghasemi, Mohsen Masoodi

Published in International Journal of Biomedical Engineering and Clinical Science (Volume 7, Issue 3)

Received: 18 June 2021 Accepted: 13 July 2021 Published: 23 August 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Recent studies have shown the diagnostic value of fecal as well as serum calprotectin in predicting the severity and activity of inflammatory bowel disease. Given the strong familial and inherited predisposition to inflammatory bowel disease, it is assumed that changes in calprotectin levels are also influenced by familial predispositions. Therefore, the present study aimed to evaluate the level of fecal calprotectin in patients and their first-degree relatives in order to determine the relationship between changes in this marker and its possible familial orientation. The study participants were the first-degree relatives (n = 100) of the patients (n = 33) with the definitive diagnosis of ulcerative colitis who referred to Rasoul-e-Akram hospital in 2018 and 2019. The fecal value of calprotectin was assessed using the ELISA method in both patients and the relatives. Fecal calprotectin level in patients was estimated to be 232.09±44.16μg/g. Fecal calprotectin level in the parents was 86.06±12.66μg/g, in siblings was 58.02±7.24μg/g and in the patient's children was 47.40±4.77μg/g. Fecal calprotectin levels were not affected by baseline indices such as gender, age, or BMI (either in patients or their relatives) and therefore these baseline factors had no effect on fecal calprotectin levels. Although fecal calprotectin levels are significantly longer in patients with ulcerative colitis than in healthy controls, the higher level of this marker among first-degree relatives of patients than healthy individuals also indicates the inherited tendency of changes in this marker in terms of high risk of disease in first-degree relatives of patients. These changes in fecal calprotectin levels will be independent of gender, age, and BMI

Published in	International Journal of Biomedical Engineering and Clinical Science (Volume 7, Issue 3)
DOI	10.11648/j.ijbecs.20210703.12
Page(s)	48-51
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Evaluation, Calprotectin Levels, Ulcerative Colitis

References

[1]	Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J gastroenterol 2014; 20: 6.
[2]	Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immuno 2008; 8: 458.
[3]	Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2017; 390: 2769-78.
[4]	Norouzinia M, Chaleshi V, Alinaghi S, Beheshti Shirazi SS, Keramatinia A, Nourian M. Evaluation of IL-12A, IL12B, IL-23A and IL-27 mRNA expression level genes in peripheral mononuclear cells of inflammatory bowel disease patients in an Iranian population. Gastroenterol Hepatol Bed Bench. 2018; 11: S45-S52.
[5]	Norouzinia M, Chaleshi V, Alizadeh AHM, Zali MR. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment. Gastroenterol Hepatol Bed Bench. 2017; 10: 155-167.
[6]	Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, et al. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflammat Bowel Dis 2015; 21: 824-31.
[7]	Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Trans Res 2012; 159: 313-25.
[8]	Foell D, Frosch M, Sorg C, Roth J. Phagocyte-specific calcium-binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta 2004; 344: 37-51.
[9]	von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-13.
[10]	Amini AK, Asadzadeh HA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Trans Gastroenterol 2017; 8: e117-e.
[11]	Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United Europ Gastroenterol J 2018:2050640618774637.
[12]	Pardi D, Sandborn W. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005; 54: 321-2.
[13]	Kadijani AA, Javadinia F, Gholamrezaei Z, Mirzaei A, Balaii H, Ghavami SB, et al. Apoptosis markers of circulating leukocytes are associated with the clinical course of inflammatory bowel disease. Gastroenterol Hepatol Bed Bench 2018; 11: S53-8.
[14]	Montalto M, Curigliano V, Santoro L, Armuzzi A, Cammarota G, Covino M, Mentella MC, Ancarani F, Manna R, Gasbarrini A, Gasbarrini G. Fecal calprotectin in first-degree relatives of patients with ulcerative colitis. Am J Gastroenterol. 2007 Jan; 102 (1): 132-6. Epub 2006 Nov 13.
[15]	Thjodleifsson B, Sigthorsson G, Cariglia N, Reynisdottir I, Gudbjartsson DF, Kristjansson K, Meddings JB, Gudnason V, Wandall JH, Andersen LP, Sherwood R, Kjeld M, Oddsson E, Gudjonsson H, Bjarnason I. Subclinical intestinal inflammation: an inherited abnormality in Crohn's disease relatives? Gastroenterology. 2003 Jun; 124 (7): 1728-37.
[16]	Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008 Jan 7; 14 (1): 53-7.

Cite This Article

Plain Text BibTeX RIS

APA Style

Solmaz Razi, Katayoon Ghasemi, Mohsen Masoodi. (2021). Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. International Journal of Biomedical Engineering and Clinical Science, 7(3), 48-51. https://doi.org/10.11648/j.ijbecs.20210703.12

Copy | Download

ACS Style

Solmaz Razi; Katayoon Ghasemi; Mohsen Masoodi. Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. Int. J. Biomed. Eng. Clin. Sci. 2021, 7(3), 48-51. doi: 10.11648/j.ijbecs.20210703.12

Copy | Download

AMA Style

Solmaz Razi, Katayoon Ghasemi, Mohsen Masoodi. Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. Int J Biomed Eng Clin Sci. 2021;7(3):48-51. doi: 10.11648/j.ijbecs.20210703.12

Copy | Download

@article{10.11648/j.ijbecs.20210703.12,
  author = {Solmaz Razi and Katayoon Ghasemi and Mohsen Masoodi},
  title = {Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis},
  journal = {International Journal of Biomedical Engineering and Clinical Science},
  volume = {7},
  number = {3},
  pages = {48-51},
  doi = {10.11648/j.ijbecs.20210703.12},
  url = {https://doi.org/10.11648/j.ijbecs.20210703.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20210703.12},
  abstract = {Recent studies have shown the diagnostic value of fecal as well as serum calprotectin in predicting the severity and activity of inflammatory bowel disease. Given the strong familial and inherited predisposition to inflammatory bowel disease, it is assumed that changes in calprotectin levels are also influenced by familial predispositions. Therefore, the present study aimed to evaluate the level of fecal calprotectin in patients and their first-degree relatives in order to determine the relationship between changes in this marker and its possible familial orientation. The study participants were the first-degree relatives (n = 100) of the patients (n = 33) with the definitive diagnosis of ulcerative colitis who referred to Rasoul-e-Akram hospital in 2018 and 2019. The fecal value of calprotectin was assessed using the ELISA method in both patients and the relatives. Fecal calprotectin level in patients was estimated to be 232.09±44.16μg/g. Fecal calprotectin level in the parents was 86.06±12.66μg/g, in siblings was 58.02±7.24μg/g and in the patient's children was 47.40±4.77μg/g. Fecal calprotectin levels were not affected by baseline indices such as gender, age, or BMI (either in patients or their relatives) and therefore these baseline factors had no effect on fecal calprotectin levels. Although fecal calprotectin levels are significantly longer in patients with ulcerative colitis than in healthy controls, the higher level of this marker among first-degree relatives of patients than healthy individuals also indicates the inherited tendency of changes in this marker in terms of high risk of disease in first-degree relatives of patients. These changes in fecal calprotectin levels will be independent of gender, age, and BMI},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis
AU  - Solmaz Razi
AU  - Katayoon Ghasemi
AU  - Mohsen Masoodi
Y1  - 2021/08/23
PY  - 2021
N1  - https://doi.org/10.11648/j.ijbecs.20210703.12
DO  - 10.11648/j.ijbecs.20210703.12
T2  - International Journal of Biomedical Engineering and Clinical Science
JF  - International Journal of Biomedical Engineering and Clinical Science
JO  - International Journal of Biomedical Engineering and Clinical Science
SP  - 48
EP  - 51
PB  - Science Publishing Group
SN  - 2472-1301
UR  - https://doi.org/10.11648/j.ijbecs.20210703.12
AB  - Recent studies have shown the diagnostic value of fecal as well as serum calprotectin in predicting the severity and activity of inflammatory bowel disease. Given the strong familial and inherited predisposition to inflammatory bowel disease, it is assumed that changes in calprotectin levels are also influenced by familial predispositions. Therefore, the present study aimed to evaluate the level of fecal calprotectin in patients and their first-degree relatives in order to determine the relationship between changes in this marker and its possible familial orientation. The study participants were the first-degree relatives (n = 100) of the patients (n = 33) with the definitive diagnosis of ulcerative colitis who referred to Rasoul-e-Akram hospital in 2018 and 2019. The fecal value of calprotectin was assessed using the ELISA method in both patients and the relatives. Fecal calprotectin level in patients was estimated to be 232.09±44.16μg/g. Fecal calprotectin level in the parents was 86.06±12.66μg/g, in siblings was 58.02±7.24μg/g and in the patient's children was 47.40±4.77μg/g. Fecal calprotectin levels were not affected by baseline indices such as gender, age, or BMI (either in patients or their relatives) and therefore these baseline factors had no effect on fecal calprotectin levels. Although fecal calprotectin levels are significantly longer in patients with ulcerative colitis than in healthy controls, the higher level of this marker among first-degree relatives of patients than healthy individuals also indicates the inherited tendency of changes in this marker in terms of high risk of disease in first-degree relatives of patients. These changes in fecal calprotectin levels will be independent of gender, age, and BMI
VL  - 7
IS  - 3
ER  -

Copy | Download

Author Information

Solmaz Razi

Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Katayoon Ghasemi

Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Mohsen Masoodi

Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Solmaz Razi, Katayoon Ghasemi, Mohsen Masoodi. (2021). Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. International Journal of Biomedical Engineering and Clinical Science, 7(3), 48-51. https://doi.org/10.11648/j.ijbecs.20210703.12

Copy | Download

ACS Style

Solmaz Razi; Katayoon Ghasemi; Mohsen Masoodi. Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. Int. J. Biomed. Eng. Clin. Sci. 2021, 7(3), 48-51. doi: 10.11648/j.ijbecs.20210703.12

Copy | Download

AMA Style

Solmaz Razi, Katayoon Ghasemi, Mohsen Masoodi. Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis. Int J Biomed Eng Clin Sci. 2021;7(3):48-51. doi: 10.11648/j.ijbecs.20210703.12

Copy | Download

@article{10.11648/j.ijbecs.20210703.12,
  author = {Solmaz Razi and Katayoon Ghasemi and Mohsen Masoodi},
  title = {Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis},
  journal = {International Journal of Biomedical Engineering and Clinical Science},
  volume = {7},
  number = {3},
  pages = {48-51},
  doi = {10.11648/j.ijbecs.20210703.12},
  url = {https://doi.org/10.11648/j.ijbecs.20210703.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijbecs.20210703.12},
  abstract = {Recent studies have shown the diagnostic value of fecal as well as serum calprotectin in predicting the severity and activity of inflammatory bowel disease. Given the strong familial and inherited predisposition to inflammatory bowel disease, it is assumed that changes in calprotectin levels are also influenced by familial predispositions. Therefore, the present study aimed to evaluate the level of fecal calprotectin in patients and their first-degree relatives in order to determine the relationship between changes in this marker and its possible familial orientation. The study participants were the first-degree relatives (n = 100) of the patients (n = 33) with the definitive diagnosis of ulcerative colitis who referred to Rasoul-e-Akram hospital in 2018 and 2019. The fecal value of calprotectin was assessed using the ELISA method in both patients and the relatives. Fecal calprotectin level in patients was estimated to be 232.09±44.16μg/g. Fecal calprotectin level in the parents was 86.06±12.66μg/g, in siblings was 58.02±7.24μg/g and in the patient's children was 47.40±4.77μg/g. Fecal calprotectin levels were not affected by baseline indices such as gender, age, or BMI (either in patients or their relatives) and therefore these baseline factors had no effect on fecal calprotectin levels. Although fecal calprotectin levels are significantly longer in patients with ulcerative colitis than in healthy controls, the higher level of this marker among first-degree relatives of patients than healthy individuals also indicates the inherited tendency of changes in this marker in terms of high risk of disease in first-degree relatives of patients. These changes in fecal calprotectin levels will be independent of gender, age, and BMI},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Evaluation of Calprotectin Levels in First-Degree Relatives of Patients with Ulcerative Colitis
AU  - Solmaz Razi
AU  - Katayoon Ghasemi
AU  - Mohsen Masoodi
Y1  - 2021/08/23
PY  - 2021
N1  - https://doi.org/10.11648/j.ijbecs.20210703.12
DO  - 10.11648/j.ijbecs.20210703.12
T2  - International Journal of Biomedical Engineering and Clinical Science
JF  - International Journal of Biomedical Engineering and Clinical Science
JO  - International Journal of Biomedical Engineering and Clinical Science
SP  - 48
EP  - 51
PB  - Science Publishing Group
SN  - 2472-1301
UR  - https://doi.org/10.11648/j.ijbecs.20210703.12
AB  - Recent studies have shown the diagnostic value of fecal as well as serum calprotectin in predicting the severity and activity of inflammatory bowel disease. Given the strong familial and inherited predisposition to inflammatory bowel disease, it is assumed that changes in calprotectin levels are also influenced by familial predispositions. Therefore, the present study aimed to evaluate the level of fecal calprotectin in patients and their first-degree relatives in order to determine the relationship between changes in this marker and its possible familial orientation. The study participants were the first-degree relatives (n = 100) of the patients (n = 33) with the definitive diagnosis of ulcerative colitis who referred to Rasoul-e-Akram hospital in 2018 and 2019. The fecal value of calprotectin was assessed using the ELISA method in both patients and the relatives. Fecal calprotectin level in patients was estimated to be 232.09±44.16μg/g. Fecal calprotectin level in the parents was 86.06±12.66μg/g, in siblings was 58.02±7.24μg/g and in the patient's children was 47.40±4.77μg/g. Fecal calprotectin levels were not affected by baseline indices such as gender, age, or BMI (either in patients or their relatives) and therefore these baseline factors had no effect on fecal calprotectin levels. Although fecal calprotectin levels are significantly longer in patients with ulcerative colitis than in healthy controls, the higher level of this marker among first-degree relatives of patients than healthy individuals also indicates the inherited tendency of changes in this marker in terms of high risk of disease in first-degree relatives of patients. These changes in fecal calprotectin levels will be independent of gender, age, and BMI
VL  - 7
IS  - 3
ER  -

Copy | Download